Stephen Maxwell Montgomery (Stephen M Montgomery, S Montgomery, Stephen Montgomery)

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 8

Top Topics

Multiple Sclerosis

Cross Sectional

Disease Activity

Top Venues

Journal of medical economics

Health science reports

Applied health economics and health policy

This page only lists publications with an associated author ORCID identifier.

Publications

Stephen Maxwell Montgomery, Luke Green, Hajer Karoui, Richard St John Nicholas, Jaclyn Loh
To wait, or too late? Modeling the effects of delayed ofatumumab treatment in relapsing-remitting multiple sclerosis. Journal of medical economics 26 (1) (2023)
Stephen Maxwell Montgomery, Luke Green, Hajer Karoui, Richard St John Nicholas, Jaclyn Loh
To wait, or too late? modeling the effects of delayed Ofatumumab treatment in relapsing-remitting Multiple Sclerosis. Journal of medical economics (2022)
Sophie Clare Laura Caseby, Fern Amy Woodhouse, Stephen Maxwell Montgomery, Michel Anton Kroes, Martin Edward Duddy
Transition to secondary progressive multiple sclerosis: The consequences for patients and healthcare systems, a healthcare professional survey. Health science reports 5 (1) (2022)
Stephen Maxwell Montgomery, Fern Amy Woodhouse, Umakanth Vudumula, K Gudala, Martin Edward Duddy, M Kroes
Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK. Journal of medical economics 25 (1) (2022)
Amir Lass, Stephen Maxwell Montgomery
RE: A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy, and Spain. Journal of medical economics 22 (4) (2019)
Kathleen Mary Noon, Stephen Maxwell Montgomery, Nicholas Edward Adlard, Michel Anton Kroes
When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis. Journal of medical economics 21 (10) (2018)
Stephen Maxwell Montgomery, Jeanette Kusel, Felicity Allen, Nicholas Adlard
Paucity and Inconsistency: A Systematic Review and Critique of Budget Impact Analyses of Disease-Modifying Therapies for Multiple Sclerosis in the UK and the Implications for Policy in the UK. Applied health economics and health policy 14 (5) (2017)
Stephen Maxwell Montgomery, Jeanette Kusel, Richard Nicholas, Nicholas Adlard
Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility. Journal of medical economics 20 (9) (2017)